More HIV news
Independent, scheduled review of Phase 3 Mosaico study finds investigational vaccine regimen lacks efficacy in preventing HIV No vaccine-related safety issues identified
U.S. FDA Approves CABENUVA (cabotegravir and rilpivirine) for Adolescents, Expanding the Indication of the First and Only Complete Long-Acting Injectable HIV Regimen
CABENUVA offers virologically suppressed adolescents 12 years of age or older living with HIV-1 an injectable treatment option with as few as six dosing days per year
U.S. FDA Approves Streamlined Process for Initiating HIV Therapy with CABENUVA (cabotegravir and rilpivirine), the First and Only Complete Long-Acting Injectable HIV Treatment
Adults living with HIV now have an option to start injectable regimen without the need for an oral lead-in period first
U.S. FDA Approves CABENUVA (rilpivirine and cabotegravir) for Use Every Two Months, Expanding the Label of the First and Only Long-Acting HIV Treatment
CABENUVA offers virologically suppressed adults living with HIV an injectable treatment option administered as few as six times a year.
Johnson & Johnson and Global Partners Announce Results from Phase 2b Imbokodo HIV Vaccine Clinical Trial in Young Women in Sub-Saharan Africa
Investigational vaccine candidate did not provide sufficient protection against HIV infection No vaccine-related safety signals identified J&J HIV vaccine program continues with global Phase 3 Mosaico HIV study evaluating a different composition of the vaccine regimen in different populations
Normally, in this part of Uganda, medication is delivered by boat—a slow, difficult process. But now a new Johnson & Johnson-supported program is using drones that can serve 20 landing sites across five islands, reaching more than 3,700 people in a single day.
“1.5 million children are living with HIV in sub-Saharan Africa. I’m one of the doctors treating these young patients every day”
A relaunched Johnson & Johnson partnership will help ensure that many young patients get lifesaving access to HIV medicines. Meet a doctor in Kenya who explains why the program is so crucial.
For World AIDS Day, we look at the groundbreaking strides the company has made—and continues to make—toward a world without the disease.
Janssen Announces Results of Phase 3 Study Demonstrating the Safety and Efficacy of Long-Acting Injectable HIV Treatment Regimen of Rilpivirine And Cabotegravir through 96 Weeks
FLAIR Phase 3 study demonstrated patient satisfaction and preference for the long-acting injectable regimen over daily oral therapy
Janssen Announces U.S. FDA Approval of CABENUVA (rilpivirine and cabotegravir), the First Long-Acting Regimen for the Treatment of HIV
CABENUVA offers adults living with HIV a new once-monthly injectable option for maintaining viral suppression
Janssen Announces Health Canada Approval of CABENUVA™, the First Long-Acting Regimen for the Treatment of HIV
CABENUVA™ offers adults living with HIV a new once-monthly injectable option for maintaining viral suppression
Janssen Announces 48-week Results of Phase 3b Study Demonstrating the Safety and Efficacy of Long-Acting Injectable HIV Treatment of Rilpivirine and Cabotegravir Administered Every Two Months
ATLAS-2M Phase 3 study demonstrated patient preference over daily oral therapy for the every-two-month administration of the long-acting injectable regimen